{
    "clinical_study": {
        "@rank": "10038", 
        "arm_group": [
            {
                "arm_group_label": "OTX-DP treatment", 
                "arm_group_type": "Experimental", 
                "description": "OTX-DP (sustained release dexamethasone, 0.4 mg)"
            }, 
            {
                "arm_group_label": "Placebo Plug Delivery Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Plug with no drug"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of OTX-DP as a sustained\n      release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the\n      treatment of the signs and symptoms of chronic allergic conjunctivitis."
        }, 
        "brief_title": "Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergic Conjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  be at least 18 years of age of either sex and any race\n\n          -  have a positive history of ocular allergies and a positive skin test reaction to a\n             perennial allergen\n\n          -  have a calculated best-corrected visual acuity of 0.7 logMAR or better in each eye as\n             measured using an ETDRS chart\n\n        Exclusion Criteria:\n\n          -  have known contraindications or sensitivities to the use of any of the\n             investigational product medication or components\n\n          -  have had ocular surgical intervention within three (3) months prior to Visit 1 or\n             during the study and/or a history of refractive surgery within the past 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062905", 
            "org_study_id": "OTX-14-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "OTX-DP treatment", 
                "intervention_name": "OTX-DP treatment", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Plug Delivery Vehicle", 
                "intervention_name": "Placebo Plug with no drug", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01810"
                }, 
                "name": "Ora, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Center, Randomized, Double-Masked, Vehicle Controlled Phase 2/3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC\u2122)", 
        "other_outcome": {
            "description": "A worsening of acuity of 10 letters or greater from the previous study visit", 
            "measure": "Distance visual acuity", 
            "safety_issue": "Yes", 
            "time_frame": "42 days"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ocular itching", 
            "safety_issue": "No", 
            "time_frame": "14 days post insertion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062905"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Conjunctival redness", 
            "safety_issue": "No", 
            "time_frame": "14 days post insertion"
        }, 
        "source": "Ocular Therapeutix, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "ORA, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Ocular Therapeutix, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}